All In Biotech

Drug Trial Radar · NCT04165993

Study of KN026 Monotherapy or Combination Therapy in Patients With Metastatic Breast Cancer

Phase II Study of Efficacy and Safety Evaluation of KN026 Monotherapy or Combination Therapy in Patients With HER2 Expressing or Positive Metastatic Breast Cancer

Last checked: Nov 19, 2026Latest source record: Sep 21, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

68

Actual

Start

Dec 31, 2019

Primary completion

May 27, 2021

Study completion Dec 31, 2025

Sponsor

Sponsor type
Industry
First posted
Nov 18, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open-label, three-cohort phase 2 study of KN026 in subjects with advanced breast Cancer.

Conditions

  • Metastatic Breast Cancer

Interventions

  • Concurrent chemotherapy and KN026Drug

    30 mg/kg Q3W KN026 75 mg/m2 docetaxol

  • KN026 monotherapyDrug

    30 mg/kg Q3W KN026

  • KN026 combinationDrug

    30 mg/kg Q3W KN026 5 mg/kg Q3W KN046

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective response rate (ORR)Time frame: Throughout the duration of the study; up to 2 years
  2. Duration of response (DOR)Time frame: up to 2 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Harbin Medical University Cancer Hospital

    Harbin, Heilongjiang, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.